A study from Watson School of Biological Sciences shows that Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling. This study was published in the April 10, 2014 Cell by Prof. Dr Scott Lowe, Watson School of Biological Sciences, CSHL, New York; Prof. Dr Carol Prives, Department of Biological Sciences, Columbia University, New York; and others.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNA-based therapy for Metastatic Pancreatic/intestine/ovarian Cancers: MiRNA-30c suppresses the expression of PDGF Receptor β (PDGFRβ) via down regulation of its target gene
Tumor suppressor p53 is mutated in about 50% of human cancers of different origin. This study suggests a therapeutic strategy as to how mutant p53 expressing human cancers can be cured. Curcumin, by suppressing the expression of PDGF Receptor β, it could inhibit the invasion of mutant p53 expressing human cancers. Thus, pharmacological formulations encompassing “MiRNA-30c activators” can be used to treat Metastatic Pancreatic/intestine/ovarian Cancers over expressing mutant p53 and PDGFRβ.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for Metastatic Pancreatic/intestine/ovarian Cancers: MiRNA-30c suppresses the expression of PDGF Receptor β (PDGFRβ) via down regulation of its target gene, 24/May/2015, 23.41, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation